文献速递创伤与烧伤重症综合管理与镇静镇痛

重大静脉损伤后静脉血栓栓塞:优先事项的权衡

Venous thromboembolism after major venous injuries: Competing priorities.
PubMed 文献 · J Trauma Acute Care Surg · 2017-01-01
一句话结论重大静脉损伤患者VTE风险高,静脉损伤为独立预测因素(OR 2.7),延迟启动药物预防预测VTE(OR 1.3/天),作者支持术后立即启动药物预防。

多机构回顾性队列研究纳入3个城市一级创伤中心2005—2013年连续435例颈部、躯干或近端肢体(至肘/膝)重大血管损伤患者,主要终点为VTE(深静脉血栓或肺栓塞)。VTE组(n=108)较无VTE组(n=327)损伤严重度评分更高(17 vs 12)、休克指数更高(1 vs 0.9)、躯干伤更多(58% vs 35%)、静脉损伤更多(73% vs 48%),接受术中全身抗凝(39% vs 53%)和术后依诺肝素预防(47% vs 61%)更少。校正后静脉损伤独立预测VTE(OR 2.7,P=0.002);静脉损伤亚组(n=237)中仅延迟启动VTE药物预防独立预测VTE(OR 1.3/天,P=0.013)。静脉损伤患者肺栓塞发生率3.4%,与手术方式无关(P=0.72)。作者认为结果支持重大静脉损伤患者术后立即启动药物预防。

要点

  • 重大静脉损伤患者VTE发生率高,静脉损伤本身独立预测VTE(OR 2.7,P=0.002)。
  • 静脉损伤亚组中,延迟启动VTE药物预防独立预测VTE(OR 1.3/天,P=0.013)。
  • VTE组术后依诺肝素预防使用率低于无VTE组(47% vs 61%,P<0.05)。
  • 静脉损伤患者肺栓塞发生率3.4%,与手术处理方式无关(P=0.72)。
  • 作者认为结果支持重大静脉损伤患者术后立即启动药物预防。

适用人群与场景

  • 纳入颈部、躯干或近端肢体(至肘/膝)重大血管损伤患者,来自3个城市一级创伤中心2005—2013年连续病例。
  • 共435例,主要为年轻(27岁)男性(89%),穿透伤(84%)。

处置流程与药物剂量

  • 作者认为重大静脉损伤患者术后应立即启动药物预防(原文结论:support the immediate initiation of postoperative chemoprophylaxis)。
  • 原文报告术后依诺肝素预防在VTE组使用47%、无VTE组使用61%(P<0.05),未给出具体剂量方案。

研究设计与关键结果

  • 多机构回顾性队列研究,3个城市一级创伤中心,435例重大血管损伤患者,主要终点为VTE(深静脉血栓或肺栓塞)。
  • VTE组(n=108)vs 无VTE组(n=327):损伤严重度评分17 vs 12,休克指数1 vs 0.9,躯干伤58% vs 35%,静脉损伤73% vs 48%,术中全身抗凝39% vs 53%,术后依诺肝素预防47% vs 61%(均P<0.05)。
  • 校正损伤严重度评分、血流动力学、损伤血管、术中抗凝和术后预防后,静脉损伤独立预测VTE(OR 2.7,P=0.002)。
  • 静脉损伤亚组(n=237)多变量分析:仅延迟启动VTE药物预防独立预测VTE(OR 1.3/天,P=0.013)。
  • 静脉损伤患者肺栓塞发生率3.4%,肺栓塞率与手术处理方式无关(P=0.72)。

证据类型、等级与局限

  • 证据类型:多机构回顾性队列研究;证据等级:治疗/照护管理,level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,重大静脉损伤患者无论术中如何处理,术后均应立即启动药物预防,以降低VTE风险。
  • 延迟启动VTE药物预防与VTE风险增加相关(OR 1.3/天),提示应尽早启动。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Venous thromboembolism (VTE) after major vascular injury (MVI) is particularly challenging because the competing risk of thrombosis and embolization after direct vessel injury must be balanced with risk of bleeding after surgical repair. We hypothesized that venous injuries, repair type, and intraoperative anticoagulation would influence VTE formation after MVI.

METHODS: A multi-institution, retrospective cohort study of consecutive MVI patients was conducted at three urban, Level I centers (2005-2013). Patients with MVI of the neck, torso, or proximal extremities (to elbows/knees) were included. Our primary study endpoint was the development of VTE (DVT or pulmonary embolism [PE]).

RESULTS: The 435 major vascular injury patients were primarily young (27 years) men (89%) with penetrating (84%) injuries. When patients with (n = 108) and without (n = 327) VTE were compared, we observed no difference in age, mechanism, extremity injury, tourniquet use, orthopedic and spine injuries, damage control, local heparinized saline, or vascular surgery consultation (all p > 0.05). VTE patients had greater Injury Severity Score (ISS) (17 vs. 12), shock indices (1 vs. 0.9), and more torso (58% vs. 35%) and venous (73% vs. 48%) injuries, but less often received systemic intraoperative anticoagulation (39% vs. 53%) or postoperative enoxaparin (47% vs. 61%) prophylaxis (all p < 0.05). After controlling for ISS, hemodynamics, injured vessel, intraoperative anticoagulation, and postoperative prophylaxis, multivariable analysis revealed venous injury was independently predictive of VTE (odds ratio, 2.7; p = 0.002). Multivariable analysis of the venous injuries subset (n = 237) then determined that only delay in starting VTE chemoprophylaxis (odds ratio, 1.3/day; p = 0.013) independently predicted VTE after controlling for ISS, hemodynamics, injured vessel, surgical subspecialty, intraoperative anticoagulation, and postoperative prophylaxis. Overall, 3.4% of venous injury patients developed PE, but PE rates were not related to their operative management (p = 0.72).

CONCLUSION: Patients with major venous injuries are at high risk for VTE, regardless of intraoperative management. Our results support the immediate initiation of postoperative chemoprophylaxis in patients with major venous injuries.

LEVEL OF EVIDENCE: Therapeutic/care management, level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Frank B, Maher Z, Hazelton JP, et al. Venous thromboembolism after major venous injuries: Competing priorities. J Trauma Acute Care Surg. 2017. PMID: 28700413. doi:10.1097/TA.0000000000001655

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。